EUVIMEDEUVIMED entdecken
Crossref

Performance of Control Arms in Trials Leading to FDA Cancer Drug Approvals

Angela Viggiano, Fabio Salomone, Fabiana Napolitano, Luigi Liguori, Annarita Avanzo, Simeone D'Ambrosio, Filippo Vitale, Maria Carmela Isernia, Anna Russo, Lucia Longo, Felice Pepe, Antonio Santaniello und 6 weitere

Journal of the National Comprehensive Cancer Network · 2026

DOI: 10.6004/jnccn.2025.7093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026. Verfasst von Angela Viggiano und 17 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Drug Approval, Neoplasms, Antineoplastic Agents, Clinical Trials as Topic. Die Arbeit nennt 102 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Selecting an appropriate control arm is essential when evaluating the efficacy of new anticancer therapies.

Methods

We analyzed the progression-free survival (PFS) performance of control arms in trials leading to FDA drug approvals between January 2014 and December 2023 for the treatment of advanced solid cancers. For each phase III or double-arm phase II trial, we extracted (1) the assumed median PFS (amPFS) value for the control arm, as specified in the study protocol for sample-size calculation, and (2) the observed median PFS (omPFS) and its confidence interval (CI) for that arm. Control arms were categorized as underperforming when the amPFS was greater than the upper bound of the omPFS CI, and as outperforming when the amPFS was lower than the lower bound of the omPFS CI. All remaining cases were classified as “within the range.” Results: We identified 72 trials that led to new cancer drug approvals. Overall, control arms underperformed in 24 of 72 (33.3%) trials and outperformed in 8 of 72 (11.1%), while the remaining 40 (55.5%) fell “within the range.” Notably, control arms underperformed in 12 of 25 (48.0%) trials leading to approvals of immune checkpoint inhibitors and in 7 of 25 (18.9%) trials leading to approvals of targeted therapies. By tumor type, underperformance occurred in 6 of 14 (42.9%) lung cancer trials, 5 of 16 (31.3%) breast cancer trials, and 5 of 16 (31.3%) genitourinary cancer trials. In 18 of the 24 (75.0%) underperforming control arms, the discrepancy between amPFS and omPFS exceeded 20%. Among the 18 trials with underperforming control arms that received expedited approval, a final overall survival advantage was not demonstrated in 7 (38.9%) cases.

Conclusions

The PFS benefit observed in several trials leading to FDA approval of new anticancer drugs may have been influenced by shorter-than-expected PFS in the control arms. Accurate analysis of control-arm outcomes in clinical trials is therefore essential to ensure an accurate and comprehensive assessment of the efficacy of experimental therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalNeoplasmsAntineoplastic AgentsClinical Trials as TopicHumansUnited StatesUnited States Food and Drug AdministrationProgression-Free Survival

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • 1Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • 2Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.
  • 3Department of Clinical Medicine, Surgery and Dentistry "Scuola Medica Salernitana," University of Salerno, Baronissi, Italy.
  • 4Department of Pneumology and Oncology, PO Monaldi-AORN Ospedali dei Colli, Naples, Italy.

Zitieren

APA

Viggiano, A., Salomone, F., Napolitano, F., Liguori, L., Avanzo, A., D'Ambrosio, S., Vitale, F., Isernia, M. C., Russo, A., Longo, L., Pepe, F., Santaniello, A., Viscardi, G., Vitiello, F., Gilli, M., Formisano, L., Bianco, R., & Servetto, A. (2026). Performance of Control Arms in Trials Leading to FDA Cancer Drug Approvals. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2025.7093

Vancouver

Viggiano A, Salomone F, Napolitano F, Liguori L, Avanzo A, D'Ambrosio S, et al. Performance of Control Arms in Trials Leading to FDA Cancer Drug Approvals. Journal of the National Comprehensive Cancer Network. 2026. doi:10.6004/jnccn.2025.7093

BibTeX
@article{Viggiano2026,
  author = {Viggiano, Angela and Salomone, Fabio and Napolitano, Fabiana and Liguori, Luigi and Avanzo, Annarita and D'Ambrosio, Simeone and Vitale, Filippo and Isernia, Maria Carmela and Russo, Anna and Longo, Lucia and Pepe, Felice and Santaniello, Antonio and Viscardi, Giuseppe and Vitiello, Fabiana and Gilli, Marina and Formisano, Luigi and Bianco, Roberto and Servetto, Alberto},
  title = {Performance of Control Arms in Trials Leading to FDA Cancer Drug Approvals},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  doi = {10.6004/jnccn.2025.7093}
}
Kostenlos starten →